Multiple sclerosis (MS) as a chronic, degenerative autoimmune disease of the central
nervous system has a longitudinal and heterogeneous course with increasing treatment …

More than 700,000 people suffer from multiple sclerosis (MS) in Europe. This implies that
more than 1 million people are affected by this disease through their role as caregivers and …

Purpose Vascular comorbidities are prevalent and can contribute to adverse health
outcomes in persons with multiple sclerosis (PwMS). Understanding the association …

The view that it is better for life to be created free from disability is pervasive in both common
sense and philosophy. We cast doubt on this view by focusing on an influential line of …

Background No previous studies have assessed the psychometric properties of the 36-item
version of the World Health Organization Disability Assessment Schedule 2.0 (WHODAS …

Abstract The Timed 25 Foot Walk (T25FW), a test of maximum walking speed on a short
distance, is commonly used to monitor ambulation status and to assess treatment outcomes …

Materials and Methods: One hundred and one MS patients who living in Khouzestan
participated in the cross-sectional study. Two questionnaires include the MSQoL-54 and …

Background Neuropsychiatric symptoms and reduced health-related quality of life (HRQoL)
are frequent in multiple sclerosis, where are associated with structural brain changes, but …

Purpose To establish reference values for Health Related Quality of Life (HRQoL) in a Dutch
rehabilitation population, and to study effects of patient characteristics, diagnosis and …

Background Fampridine improves walking in patients with multiple sclerosis (pwMS).
However, little is known about its impact on the quality of life (QoL) of pwMS. Objectives This …